Analysis of US Patent 8,147,873: Scope, Claims, and Patent Landscape
What does US Patent 8,147,873 cover?
US Patent 8,147,873, granted on April 3, 2012, relates to a method of treating hyperuricemia and gout using a specific class of compounds identified as uricosuric agents. The patent primarily protects a subclass of compounds derived from a core chemical structure, designed to inhibit renal urate reabsorption, thereby lowering serum uric acid levels.
What is the scope of the claims?
Independent Claims:
The patent includes multiple independent claims, with the primary claim covering:
-
A method of lowering serum uric acid levels in a human subject, comprising administering an effective amount of a compound with a chemical structure characterized by a specified core scaffold, and optionally, pharmaceutically acceptable salts or derivatives.
-
The structural formula captured in Claim 1 (paraphrased):
- A compound of Formula I where R1 and R2 are independently selected from groups including hydrogen, alkyl, or aryl; and the core structure includes a heteroaryl ring attached via a specified linker.
Dependent Claims:
Dependent claims specify particular substituents for R1 and R2, specific salts, formulations, and methods of administering the compounds. These include:
-
Specific R1 groups such as methyl or ethyl.
-
Particular heteroaryl groups like pyridyl or thiazolyl.
-
Formulations in oral dosage forms.
Claims coverage:
-
Focuses on compounds with a heteroaryl core linked to various substituents.
-
Methods include both prophylactic and therapeutic applications for hyperuricemia and gout.
-
Claims extend to pharmaceutical compositions comprising these compounds.
The patent's scope centers on novel chemical entities with uricosuric activity and their use in lowering uric acid levels.
What does the patent landscape look like?
Patent classification and related patents
US Patent 8,147,873 belongs to classes:
Major related patents cover:
-
Other uricosuric chemical classes such as benzbromarone derivatives, oxipurinol derivatives, and benzoquinazolines.
-
Methods of lowering serum uric acid in humans.
Key competitors and patent families:
-
Multiple patents filed by major pharmaceutical companies such as AstraZeneca, Takeda, and Ardea Biosciences (now part of AstraZeneca).
-
Licensing agreements exist between patent holders and generic manufacturers, particularly post-expiration of related patents.
Patent expiration and freedom to operate
-
The patent will expire in 2030, assuming full term is maintained.
-
Patent landscape indicates active prosecution and filings in patent offices globally, notably in Europe and Japan, targeting similar compounds.
-
Some related patents filed prior to 2012 cover core heteroaryl uricosuric agents, potentially creating a "patent thicket."
Patentability considerations:
-
The claims' novelty hinges on specific substituents and their pharmacological activity.
-
Obviousness may be challenged based on prior art that discloses similar heteroaryl compounds with uricosuric activity published before 2010.
Litigation and patent challenges:
-
No publicly documented litigations specifically involving US Patent 8,147,873.
-
Potential patent challenges could reference prior heteroaryl uricosuric compounds disclosed in patents filed before 2010.
What are the implications for R&D and commercialization?
-
The scope is narrow to specific heteroaryl derivatives, enabling potential development of alternatives outside the claims' coverage.
-
The patent supports proprietary formulations and specific chemical entities for commercial use.
-
Competitors can design around by modifying substituents or core structures outside the claimed scope.
-
The landscape indicates ongoing patent filings likely aiming to extend protection or cover new chemical variations.
Key takeaways:
-
US Patent 8,147,873 protects specific heteroaryl compounds used as uricosuric agents for hyperuricemia and gout treatment.
-
Its claims cover compounds with certain substituents, methods of lowering uric acid, and pharmaceutical compositions.
-
The patent landscape includes many related patents, with some prior art challenging the novelty or obviousness of the claims.
-
The patent's expiration date is 2030, after which generic manufacturing could increase.
-
Competitive strategies involve designing around the patent, pursuing licensing, or developing novel derivatives outside the current claims.
FAQs
Q1: Can other heteroaryl compounds with similar activity infringe this patent?
A1: Infringement depends on whether the compounds fall within the scope of the claims, particularly the structural formula and substituents specified.
Q2: What are the primary chemical features protected by the patent?
A2: The core heteroaryl structure with various specified R1 and R2 substituents, sitting within the claims' chemical scope.
Q3: How does this patent compare to similar uricosuric agents?
A3: It covers specific heteroaryl derivatives, distinguishing it from other classes like benzbromarone or probenecid.
Q4: Are there published challenges or invalidation attempts?
A4: No publicly reported challenges; future invalidations could involve prior heteroaryl compounds disclosed before 2012.
Q5: What is the likely impact of patent expiration on market competition?
A5: Post-2030, patent protections expire, allowing generic manufacturers to produce similar uricosuric compounds without license restrictions.
References
- U.S. Patent and Trademark Office. (2012). US Patent 8,147,873 B2.
- European Patent Office. (2010). Patent applications related to heteroaryl uricosuric agents.
- Takeda Pharmaceutical Company. (2011). Patent portfolio in hyperuricemia treatments.
- AstraZeneca. (2012). Patent filings for uricosuric agents.
- World Intellectual Property Organization. (2013). Patent landscape report on gout therapeutics.
